📇 Rhumatologue · CRETEIL CEDEX · (94) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
36 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP HM SITE HENRI MONDOR
51 AV MAL DE LATTRE DE TASSIGNY, 94010 CRETEIL CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Annals of the rheumatic diseases · 2018
Arthritis & rheumatology (Hoboken, N.J.) · 2017
ObjectiveIn most patients with nonsevere systemic necrotizing vasculitides (SNVs), remission is achieved with glucocorticoids alone, but one‐third experience a relapse within 2 years. This study was undertaken to determine whether the addition of azathioprine (AZA) to glucocorticoids could achieve a higher sustained remission rate of newly diagnosed nonsevere eosinophilic granulomatosis with polyangiitis (Churg‐Strauss) (EGPA), microscopic polyangiitis (MPA), or polyarteritis nodosa (PAN).MethodsAll patients included in this double‐blind trial received glucocorticoids, gradually tapered over 12 months, and were randomized to receive AZA or placebo for 12 months, with stratification according to SNV (EGPA or MPA/PAN). The primary end point was the combined rate of remission induction failures and minor or major relapses at month 24.ResultsNinety‐five patients (51 with EGPA, 25 with MPA, and 19 with PAN) met the inclusion criteria, were randomized, and received at least 1 dose of AZA (n = 46) or placebo (n = 49). At month 24, 47.8% of the patients receiving AZA versus 49% of the patients receiving placebo had remission induction failures or relapses (P = 0.86). Secondary end points were comparable between the AZA and placebo arms. These included initial remission rate (95.7% versus 87.8%), total relapse rate (44.2% versus 40.5%), and glucocorticoid use. Two patients in the placebo arm died; 22 patients in the AZA arm (47.8%) and 23 patients in the placebo arm (46.9%) experienced ≥1 severe adverse event. For EGPA patients, the primary end point (48% in the AZA arm versus 46.2% in the placebo arm) and the percent of patients who experienced asthma/rhinosinusitis exacerbations (24% in the AZA arm versus 19.2% in the placebo arm) were comparable between treatment arms.ConclusionAddition of AZA to glucocorticoids for the induction of remission of nonsevere SNVs does not improve remission rates, lower relapse risk, spare steroids, or diminish the EGPA asthma/rhinosinusitis exacerbation rate.
Medicine · 2016
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of the American Academy of Dermatology · 2026 · Journal Article
Cottu A, Grolleau C, Gandon C, Mahévas T, et al.
Annals of internal medicine · 2025 · Journal Article
Terrier B, Pugnet G, de Moreuil C, Bonnotte B, et al.
Annals of the rheumatic diseases · 2024 · Journal Article
Delestre F, Charles P, Karras A, Pagnoux C, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Morel P, Karras A, Porcher R, Belenfant X, et al.
American journal of hematology · 2022 · Letter
De Luna G, Habibi A, Odièvre MH, Guillet H, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Sorin B, Samson M, Durel CA, Diot E, et al.
Haematologica · 2021 · Journal Article
Mahévas M, Azzaoui I, Crickx E, Canoui-Poitrine F, et al.
Arthritis research & therapy · 2020 · Journal Article
Mekinian A, Saadoun D, Vicaut E, Thietart S, et al.
Clinical and experimental rheumatology · 2016 · Clinical Trial, Phase III
Pugnet G, Pagnoux C, Terrier B, Perrodeau E, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2026 · Journal Article
Eshagh D, Quéméneur T, Karras A, Queyrel V, et al.
The journal of allergy and clinical immunology. In practice · 2025 · Journal Article
Stammler R, Vallée A, Rohmer J, Grardel N, et al.
Virchows Archiv : an international journal of pathology · 2025 · Journal Article
Bernhard E, Sakhi H, Oniszczuk J, Guillaud C, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Rheumatology (Oxford, England) · 2022 · Randomized Controlled Trial
David C, Duployez N, Eloy P, Belhadi D, et al.
Journal of internal medicine · 2022 · Letter
David C, Costedoat-Chalumeau N, Belhadi D, Laouénan C, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Annals of the rheumatic diseases · 2024 · Journal Article
Delestre F, Charles P, Karras A, Pagnoux C, et al.
Annals of the rheumatic diseases · 2018 · Journal Article
Terrier B, Pagnoux C, Perrodeau É, Karras A, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Sorin B, Samson M, Durel CA, Diot E, et al.
Arthritis research & therapy · 2020 · Journal Article
Blanchet B, Jallouli M, Allard M, Ghillani-Dalbin P, et al.
Lupus · 2016 · Journal Article
British journal of haematology · 2023 · Observational Study
Crickx E, Ebbo M, Rivière E, Souchaud-Debouverie O, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Letter
Stammler R, Bessis D, Meunier L, Limal N, et al.
British journal of haematology · 2022 · Journal Article
Sokal A, de Nadaï T, Maquet J, Comont T, et al.
British journal of haematology · 2022 · Journal Article
Sokal A, de Nadaï T, Maquet J, Comont T, et al.
Autoimmunity reviews · 2021 · Letter
Moussiegt A, Müller R, Ebbo M, Grados A, et al.
British journal of haematology · 2021 · Letter
Crickx E, Moulis G, Ebbo M, Terriou L, et al.
The Lancet. Rheumatology · 2022 · Observational Study
Murarasu A, Guettrot-Imbert G, Le Guern V, Yelnik C, et al.
Kidney international · 2021 · Letter
Oniszczuk J, Pagot E, Limal N, Hüe S, et al.
The Lancet. Rheumatology · 2023 · Multicenter Study
de Frémont GM, Costedoat-Chalumeau N, Lazaro E, Belkhir R, et al.
Arthritis research & therapy · 2020 · Journal Article
Mekinian A, Saadoun D, Vicaut E, Thietart S, et al.
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
Abstract Objectives To assess long-term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK). Methods Prospective open-labeled trial in naïve patients with TAK who received steroids at the do
Information Flow Decomposition in Feedback Systems: General Case Study
We derive three fundamental decompositions on relevant information quantities in feedback systems. The feedback systems considered in this paper are only restricted to be causal in time domain and the channels are allowe
Additional file 1 of Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence
Additional file 1.
An Information Identity for State-dependent Channels with Feedback
In this technical note, we investigate information quantities of state-dependent communication channels with corrupted information fed back from the receiver. We derive an information identity which can be interpreted as
Additional file 1 of Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence
Additional file 1.
Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence
Abstract Background Hydroxychloroquine (HCQ) levels can be measured in both serum and whole blood. No cut-off point for non-adherence has been established in serum nor have these methods ever been compared. The aims of t
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Maillet F, Nguyen Y, Espitia O, Perard L, et al.
Allergy · 2025 · Journal Article
Lefèvre G, Bleuse S, Puyade M, Moulis G, et al.
Journal of clinical medicine · 2022 · Journal Article
Trefond L, Frances C, Costedoat-Chalumeau N, Piette JC, et al.
Rheumatology (Oxford, England) · 2019 · Journal Article
Puéchal X, Pagnoux C, Baron G, Lifermann F, et al.
European journal of internal medicine · 2017 · Letter
Moulis G, Guénin S, Limal N, Michel M, et al.
Medicine · 2016 · Journal Article
Thai LH, Mahévas M, Roudot-Thoraval F, Limal N, et al.
Larosa M, Le Guern V, Guettrot-Imbert G, Morel N, et al.
Lupus · 2022 · Case Reports
Matthys A, Megdiche I, Bardel B, Remy P, et al.
Rheumatology (Oxford, England) · 2021 · Journal Article
Chezel J, Costedoat-Chalumeau N, Laouénan C, Rouzaud D, et al.
Arthritis research & therapy · 2020 · Journal Article
Blanchet B, Jallouli M, Allard M, Ghillani-Dalbin P, et al.
Lupus · 2016 · Journal Article
Jolly M, Galicier L, Aumaître O, Francès C, et al.
La Revue de medecine interne · 2016 · Journal Article
Mathian A, Arnaud L, Adoue D, Agard C, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2017 · Journal Article
Puéchal X, Pagnoux C, Baron G, Quémeneur T, et al.
Clinical and experimental rheumatology · 2016 · Clinical Trial, Phase III
Pugnet G, Pagnoux C, Terrier B, Perrodeau E, et al.
Jolly M, Galicier L, Aumaître O, Francès C, et al.